Eskazan Ahmet Emre, Keskin Dilek
Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Kocamustafapasa/Fatih, 34303 Istanbul, Turkey.
Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Ther Adv Hematol. 2017 Sep;8(9):237-243. doi: 10.1177/2040620717719851. Epub 2017 Jul 25.
Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations for treating patients in the upfront setting. Radotinib (IY5511HCL, ) is a novel and selective second-generation BCR-ABL1 TKI, which is currently approved in Korea for the treatment of patients with CML both in the upfront and salvage settings. This review mainly focuses on the clinical potential of radotinib in patients with CML in chronic phase in terms of efficacy and safety.
虽然伊马替尼显著改善了慢性髓性白血病（CML）患者的主要治疗结局，但全球已有新型酪氨酸激酶抑制剂（TKIs）被批准用于治疗耐药病例，并且在一些国家，两种第二代TKIs（达沙替尼、尼洛替尼）被批准用于一线治疗患者。拉多替尼（IY5511HCL）是一种新型选择性第二代BCR-ABL1 TKI，目前在韩国被批准用于一线和挽救性治疗CML患者。本综述主要从疗效和安全性方面聚焦拉多替尼在慢性期CML患者中的临床潜力。
